Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Seattle Genetics, Inc.
Seattle Genetics Reports Strong Pipeline Progress and Second Quarter 2009 Financial Results
August 3rd, 2009
Seattle Genetics, Inc. (Nasdaq: SGEN) reported financial results for the second quarter and six months ended June 30, 2009. The company also highlighted recent product development progress. "The second quarter featured strong clinical data presentations with SGN-35, now named brentuximab vedotin, that continue to demonstrate a compelling objective response rate and tolerability profile in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL)," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "In both of our phase I clinical trials, brentuximab vedotin achieved complete or partial responses in greater than...
Source: Clinical Trials Week (2009-08-03)
|
